A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

NCT06672939 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the medication Orforglipron (LY3502970) in teenagers who have obesity or are overweight with related health issues to see how it affects their body mass index (BMI).

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 150 people Planned (estimated).

Who can join Ages 12–17 · all sexes

Timeline Started 2024-11 · est. completion 2031-01

Where 40 sites · Israel, Italy, Japan, Poland, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT06672939 ↗

Description as written by the study sponsor.

The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with obesity, or overweight with related comorbidities. Participation in the study will last about 18 months. Participants who have completed the primary PW01 study (including the 4-week safety follow-up period) will have the opportunity to receive an additional 156 weeks of treatment with orforglipron as well as continuing the lifestyle intervention.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Percent Change from Baseline in Body Mass Index (BMI)
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06672939 ↗